Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 3 55-3, 2004, Pages

  Schultz, Jo El J ^a   Glascock, Betty J ^a   Witt, Sandra A ^a   Nieman, Michelle L ^a   Nattamai, Kalpana J ^b   Liu, Lynne H ^b   Lorenz, John N ^a   Shull, Gary E ^a   Kimball, Thomas R ^a   Periasamy, Muthu ^b,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac dysfunction; Echocardiography; Knockout mice; Sarco(endo)plasmic reticulum calcium adenosine 5 triphosphatase pump

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); SERCA2 PROTEIN; SERCA2A PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA COARCTATION; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GRAVIMETRY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART VENTRICLE OVERLOAD; HEMODYNAMICS; HISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 10744230243     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00720.2003     Document Type: Article

References (36)

1. Arai M, Alpert NR, MacLennan DH, Barton P, and Periasamy M. Alterations in sarcoplasmic reticulum gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72: 463-469, 1993.
2. Arai M, Matsui J, and Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 74: 555-564, 1994.
3. Bavendiek U, Brixius K, Munch G, Zobel C, Muller-Ehmsen J, and Schwinger RH. Effect of inotropic interventions on the force-frequency relation in the human heart. Basic Res Cardiol 93, Suppl 1: 76-85, 1998.
4. Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW 2nd, and Kranias EG. Interactions between phospholamban and β-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103: 889-896, 2001.
5. De Boer RA, Henning RH, Suurmeijer AJ, Pinto YM, Olthof E, Kirkels JH, van Gilst WH, Crijns HJ, and van Veidhuisen DJ. Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease. Int J Cardiol 78: 5-12, 2001.
6. 2+-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res 66: 554-564, 1990.
7. Del Monte F, Hajjar RJ, and Harding SE. Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ Res 88: E66-E67, 2001.
8. 2+ ATPase in a rat model of heart. Circulation 104: 1424-1429, 2001.
9. Feldman AM, Weinberg EO, Ray PE, and Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 73: 184-192, 1993,
10. Freeman K, Lerman I, Kranias EG, Bohimeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, and Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 107: 967-974, 2001.
11. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 37: 279-289, 1998.
12. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 75: 434-442, 1994.
13. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 100: 380-389, 1997.
14. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, Wang Y, Ross J Jr, and Chien KR. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8: 864-871, 2002.
15. 2+ ATPase modifies the transition from hypertrophy to early heart failure. Circ Res 89: 422-429, 2001.
16. 2+ homeostasis and cardiomyocyte function. J Biol Chem 275: 38073-38080, 2000.
17. Kiriazis H, Sato Y, Kadambi VJ, Schmidt AG, Gerst MJ, Hoit BD, and Kranias EG. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis. Cardiovasc Res 53: 372-381, 2002.
18. 2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res 77: 759-764, 1995.
19. 2+ handling capacity. Circ Res 89: 160-167, 2001.
20. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res 31: 625-632, 1996.
21. Lorenz JN and Robbins J. Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am J Physiol Heart Circ Physiol 272: H1137-H1146, 1997.
22. 2+ ATPase. Circ Res 83: 889-897, 1998.
23. Matsui H, MacLennan DH, Alpert NR, and Periasamy M. Sarcoplasmic reticulum gene expression in pressure overload-induced cardiac hypertrophy in rabbit. Am J Physiol Cell Physiol 268: C252-C258, 1995.
24. 2+-ATPase gene expression in the human ventricle during end-stage heart failure, J Clin Invest 85: 305-309, 1990.
25. Meyer M, Trost SU, Bluhm WF, Knot HJ, Swanson E, and Dillmann WH. Impaired sarcoplasmic reticulum function leads to contractile dysfunction and cardiac hypertrophy. Am J Physiol Heart Circ Physiol 280: H2046-H2052, 2001.
26. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, and Chien KR. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99: 313-322, 1999.
27. Miyamoto MI, Del Monte F, Schmidt U, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A, and Hajjar RJ. Adenoviral gene transfer of SERCA2a improves left ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 97: 793-798, 2000.
28. 2+-ATpase and phospholamban mRNA expression in response to pressure overload and thyroid hormone. Proc Natl Acad Sci USA 86: 2966-2970, 1989.
29. 2+-ATPase isoform 2 (SERCA2) gene. J Biol Chem 274: 2556-2562, 1999.
30. Pieske B, Kretschmann B, Meyer M, Holubarsch C, Posival H, Just H, and Hasenfuss G. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 92: 1169-1178, 1995.
31. 2+-ATPase during progression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 272: H2416-H2424, 1997.
32. Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, and Vatner SF. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest 110: 271-279, 2002.
33. Sahn DJ, DeMaria A, Kisslo J, and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
34. Schultz JE, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, and Doetschman T. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109: 787-796, 2002.
35. Schultz JE, Witt SA, Nieman ML, Reiser PJ, Engle SJ, Zhou M, Pawlowski SA, Lorenz JN, Kimball TR, and Doetschman T. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest 104: 709-719, 1999.
36. Williams RV, Lorenz JN, Witt SA, Hellard DT, Khoury PR, and Kimball TR. End-systolic stress-velocity and pressure-dimension relationships by transthoracic echocardiography in mice. Am J Physiol Heart Circ Physiol 274: H1828-H1835, 1998.